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Abstract: Lowe syndrome and Dent II disease are X-linked monogenetic diseases characterised by a
renal reabsorption defect in the proximal tubules and caused by mutations in the OCRL gene, which
codes for an inositol-5-phosphatase. The life expectancy of patients suffering from Lowe syndrome is
largely reduced because of the development of chronic kidney disease and related complications.
There is a need for physiological human in vitro models for Lowe syndrome/Dent II disease to study
the underpinning disease mechanisms and to identify and characterise potential drugs and drug
targets. Here, we describe a proximal tubule organ on chip model combining a 3D tubule architecture
with fluid flow shear stress that phenocopies hallmarks of Lowe syndrome/Dent II disease. We
demonstrate the high suitability of our in vitro model for drug target validation. Furthermore, using
this model, we demonstrate that proximal tubule cells lacking OCRL expression upregulate markers
typical for epithelial–mesenchymal transition (EMT), including the transcription factor SNAI2/Slug,
and show increased collagen expression and deposition, which potentially contributes to interstitial
fibrosis and disease progression as observed in Lowe syndrome and Dent II disease.
Keywords: organ-on-a-chip; disease modeling; proximal tubule-on-a-chip; Lowe syndrome; fibrosis;
microfluidic; OCRL
1. Introduction
Lowe syndrome is an X-linked monogenetic human disease mainly affecting the eye,
brain, and kidney and, thus, is also known as oculocerebrorenal syndrome, which gave
rise to the name OCRL for the gene mutated in Lowe syndrome [1,2]. Mutations in OCRL
can also be found in a subset of Dent disease patients, which led to the establishment
of a Dent II disease category for these patients [3,4]. Dent disease patients show a very
similar renal phenotype but differ from Lowe syndrome patients by not showing a major
phenotype in the nervous system or eye. Lowe syndrome and Dent II disease patients both
show a progressive reabsorption defect in the kidney that often leads to complete kidney
failure and which is the main cause for increased mortality observed in Lowe syndrome
patients [5,6].
The OCRL protein is an inositol-5-phosphatase catalysing the removal of phosphate
from the position 5′ of the inositol head group of phosphatidylinositol-4,5-bisphosphate
[PtdIns(4,5)P2] and phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P3] [7]. OCRL is a
peripheral membrane protein binding to several members of the monomeric G-protein Rab-
family [8,9]. OCRL is mainly localised at the Golgi apparatus and at early/recycling endosomes
but can also localise to lysosomes under conditions of high endocytic load [10–12]. OCRL
has been shown to play a major role as a regulator of intracellular trafficking, in particular
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contributing to the uncoating of clathrin-coated vesicles as well as regulating receptor recycling
from endosomes to the plasma membrane or to the Golgi apparatus [11,13–15]. Results from
Lowe syndrome animal models as well as from isolated proximal tubule cells from Lowe
syndrome patients reveal a role in the recycling of megalin, a receptor important for nutrient
absorption in the kidney, which accounts, at least in part, for the renal reabsorption defect
observed in Lowe syndrome and Dent II disease [15–17].
OCRL has also been reported to localise to the basal body and the transition zone of
the primary cilium [18]. Fibroblasts or proximal tubule cell lines compromised in OCRL
protein expression show fewer and shorter cilia, while knockdown of OCRL in MDCK cells
(a kidney cell line derived from the outer medullary collecting duct) has been reported to
lead to longer cilia [18–21]. Cilia play a major role in sensing and transducing chemical
and mechanical cues, and it has been reported that the lack of OCRL leads to an increase in
PtdIns(4,5)P2 levels at the transition zone of cilia causing reduced accumulation of sonic
hedgehog protein upon stimulation with a hedgehog agonist [22]; however, the role and
contribution of cilia defects to the Lowe syndrome phenotype are unclear.
Suitable model systems are key to investigating disease mechanisms and to identifying
and testing potential drugs and drug targets for Lowe syndrome. Early attempts to establish
a Lowe syndrome mouse model by knocking out the Ocrl gene failed as Ocrl KO mice did not
develop a disease phenotype [23]. The reason for this is the presence of another inositol-5-
phosphatase, INPP5B, that can compensate for the lack of OCRL in mice but not in humans.
Ocrl and Inpp5b double knockout mice are embryonically lethal; however, an Ocrl knockout
mouse with a tissue-specific knockout of Inpp5b in kidney is viable and shows a renal reab-
sorption defect [24]. Furthermore, expressing humanised INPP5B in Ocrl/Inpp5b knockout
mice shows proximal tubule dysfunction (low molecular weight proteinuria, aminoaciduria)
similar to Lowe syndrome and Dent II disease [16,25]. Finally, transgenic zebrafish embryo
models with impaired OCRL expression have been generated showing defective fluid phase
uptake and clathrin-mediated endocytosis in pronephric tubules and are more susceptible to
febrile seizures and develop cystic lesions in the brain [17,18,26,27]. However, human Lowe
syndrome model systems are currently limited to static 2D cell cultures of proximal tubule
cells or skin fibroblasts isolated from Lowe syndrome patients or kidney-derived cell lines
using knockdown or knockout technologies to impair OCRL expression.
Given the severity and life-threatening nature of the renal phenotype of Lowe syndrome
novel, more physiologically relevant human in vitro models to investigate this disease aspect
in particular are necessary. In vivo proximal tubule cells are arranged in 3D tubules and
are exposed to significant fluid flow shear stress, which is not reflected in current static
cellular models [28,29]. Here, we describe a novel proximal tubule on chip model for Lowe
syndrome and Dent II disease that phenocopies hallmarks of these diseases. Using this
model, we reveal that proximal tubule cells lacking OCRL demonstrate upregulation of
epithelial–mesenchymal transition (EMT) marker proteins and increased collagen deposition,
which may contribute to interstitial fibrosis as observed in Lowe syndrome patients.
2. Results
In order to develop an organ on chip model for Lowe syndrome, we first engineered a
suitable cellular model for Lowe syndrome by deleting OCRL protein expression in the
human proximal tubule cell line HK-2 using CRISPR/Cas9. HK-2 is a robust cell line, easy
to grow and well established in the field of proximal tubule research [30]. Lack of complete
OCRL expression has been shown previously in several Lowe syndrome patients, and
genomic nonsense and frame shift mutations leading to early premature stop codons have
been identified in Lowe syndrome and Dent II disease patients [3,31]. Thus, knocking out
OCRL is a feasible approach to model Lowe syndrome.
We chose two independent OCRL KO clones for further analysis. Lack of full-length
OCRL protein was confirmed by Western blotting and by immunofluorescence analysis
(Figure 1a,b). Genomic characterisation revealed frame shift mutations leading to predicted
early premature stop codons (Figure S1).
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Figure 1. Confirmation of OCRL KO stable cell lines: (a) Western blotting with Anti-OCRL–No OCRL protein was detected
in A3 or A4, but WT shows the band at the predicted size of 110 kDa. Anti-β tubulin at 55 kDa was used as a loading
control. (b) Immunostaining of WT and KO clones with Anti-OCRL and EEA1 (early endosomes) showing no punctate
staining for OCRL in KO clones (A3 and A4). Images were taken by Airyscan confocal microscope, scale bars: 20 µm.
Next, we investigated whether our OCRL KO cell lines displayed phenotypes previ-
ously described in cells from Lowe syndrome patients and, thus, could serve as a suitable
cellular model for Lowe syndrome in principle. A hallmark of Lowe syndrome (and Dent
II disease) is a reabsorption defect in proximal tubule cells. Reabsorption in proximal
tubules takes place mainly via the megalin/cubilin receptor system. Megalin also binds
the receptor-associated protein RAP, which serves as an exocytic traffic chaperone and
inhibits ligand binding to the receptor [32]. Using a recombinant GST–RAP fusion protein,
we exploited the specific binding of RAP to megalin to monitor and quantify megalin-
mediated endocytosis in wild-type and OCRL KO HK-2 cells [15]. We observed that OCRL
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KO cell lines showed a significantly reduced uptake of RAP compared to wild-type HK-2
cells at all time points investigated (Figure S2). Previously, it has also been reported that
reduced reabsorption is, at least in part, due to the reduced cell surface expression levels of
megalin [15,17]. This is in line with our finding of reduced cell surface binding of GST–RAP
to OCRL KO HK-2 cells (Figure S3). We also observed increased F-actin co-localisation
with EEA1, reflecting aberrant actin polymerisation at early endosomes, likely due to the
elevated PtdIns(4,5)P2 levels as described previously (Figure S4) [15]. Furthermore, we
observed mis-sorting of CI-M6PR to early endosomes (Figure S5) also as described previ-
ously [33]. Overall, our findings are in line with a previously described characterisation of
HK-2 OCRL KO cells [34].
In vivo proximal tubule cells form a 3D laminated structure and are exposed to
significant mechanical stress in the form of fluid shear stress. This 3D architecture combined
with fluid shear stress is an important regulator of cellular homeostasis and is, so far, lacking
in current in vitro models for Lowe syndrome.
Having demonstrated that our OCRL KO HK-2 cell lines display hallmarks of the phe-
notype described previously for cells isolated from Lowe syndrome patients, or in animal
Lowe syndrome models, we incorporated our cell lines into a three-lane OrganoPlate®.
OrganoPlate is a recently developed microfluidic platform that allows for the growth of 3D
proximal tubules in a microfluidic setup [35–37]. Cells were seeded into the top channel,
then the middle channel was filled with ECM (collagen I) and the bottom channel was
filled with medium. Cells were grown for several days under fluid flow stress by placing
the plates on a rocker using gravity to induce fluid flow and form a three-dimensional
tubule with a hollow lumen (Figure 2). To test the integrity of the 3D tubules formed in the
OrganoPlate setup, we used a dextran diffusion assay by loading fluorescently labelled
dextran (20 kDa or 155 kDa) into the top channel and followed diffusion into the middle
and bottom channel over a time course of 14 min using fluorescence microscopy. Tubules
formed by wild-type or OCRL KO HK-2 cells did not show any significant diffusion of flu-
orescently labelled dextran into the middle and bottom channels, whereas dextran loaded
into the top channel housing no tubules as a control leaked into the middle and bottom
channels (Figure 3). We concluded that OCRL KO cells could form leak-tight tubules.
Figure 2. Proximal tubule on a chip: (a) 3-lane OrganoPlate® with 40 chips, a pictorial representation of a single chip with
all its wells (A: cell inlet, B: gel inlet, C: medium inlet, D: cells outlet, E: gel outlet, F: medium outlet and G: observation
window). The observation window (G) with the top lane shows when cells adhere against the gel in the middle lane
followed by cells forming a tubule at Day 5. (b) Immunostaining images of the 3D proximal tubule grown in OrganoPlate
with acetylated tubulin (green); scale bar: 500 µm.
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Figure 3. Barrier integrity assay: (a) a cartoon of the 3-lane OrganoPlate microfluidic chips with a top
perfusion channel with cells, middle gel channel and bottom medium channel. When dye-containing
medium was added in the lumen, the dye did not permeate into the gel channel if the tubule was leak
tight. (b) If the tubule was leaky or in cell-free control chips, the dye diffused into the gel channel.
(c) Images of the leak-tight tubules of HK-2 cells in WT and OCRL KO clones (A3 and A4) vs. a
cell-free control for leakiness for both 20 kDa FITC Dextran and 155 kDa TRITC Dextran molecules.
(d,e) Graphs showing the curve for the cell-free control chip with the diffusion of the dye and its
normalised fluorescence intensity increasing over the duration of the assay (14 min). Leak-tight
tubules had stable ratios of signal intensities in the perfusion channel vs. the gel channel. The XY
graph was plotted with the mean and SD values, N = 3. Each N had values from at least 5 chips
per sample.
In zebrafish models for Lowe syndrome and fibroblasts isolated from Lowe syndrome
patients, defects in cilia formation have been reported [18,21,27]. We tested whether this
was also the case for human HK-2 cells lacking OCRL and which have been exposed to
fluid flow stress similar to the situation in the human kidney or zebrafish pronephros. Both
OCRL KO clones investigated showed significantly reduced cilia length (Figure 4).
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Figure 4. Cilia defect in Lowe syndrome cells under fluid flow: (a) immunofluorescence images showing HK-2 cells (WT
and OCRL KO (A3, A4)) grown in OrganoPlate and stained with acetylated tubulin and PCNT to visualise primary cilia
(green) and pericentrin (orange), respectively. Images were captured using the Perkin Elmer Operetta CLS with 20X water
objective. Two adjacent fields were stitched together for visual purposes of the tubule. (b) Quantitative analysis of cilia
length measured using segmented tool in ImageJ software and represented as a scatter plot with individual values. Ordinary
one-way ANOVA and Dunnett’s multiple comparison test, N = 3 (>50 cells per N). ***, p < 0.001; ****, p < 0.0001, error bar
represents mean with ± SEM.
In order to investigate whether our model is suitable for drug target screening in prin-
ciple, we capitalised on the fact that downregulation of phosphatidylinositol-4-phospate
5-kinase alpha (PIP5 kinase α) has been shown to revert the F-actin phenotype and endocy-
tosis defect in OCRL knockdown cells [15]. We speculated that downregulation of PIP5
kinase α might also rescue cilia length in OCRL KO cells. Using an siRNA approach, we
successfully knocked down PIP5 kinase α in 3D proximal tubule cells. Subsequently, we
measured cilia length and observed that knockdown of PIP5 kinase α could rescue the cilia
length to wild-type levels in OCRL knockout clones. Interestingly, we also observed an
effect of our siRNA on wild-type cells leading to a reduced cilia length, suggesting that a
tight balance of PIP kinase and PIP phosphatase activity (Figure 5) regulates cilia length.
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Figure 5. Cilia length defect in OCRL-KO cells was rescued by PIP5K1A KD: (a) Capillary-based Western blotting (WES)
confirming a reduction in protein expression levels of the PIP5K1A gene in WT, OCRL KO A3 and A4. The first lane depicts
the biotinylated ladder at 66 kDa. The bands detected by the PIP5K1A antibody with samples of non-targeting siRNA
CTRL show a distinct band at ~65 kDa. TBP (TATA-Box Binding Protein) was used as a loading marker and detected at
~52 kDa. Images were derived from the Simple Western Compass software and used to analyse data generated by WES. (b)
An aligned dot plot with the length of cilia measured in each condition with ImageJ software segment tool. Student Welch’s
t-test, N = 3 (>50 cells per N), ****, p < 0.0001, error bar represents ± SD. (c) Immunofluorescence images showing primary
cilia stained with acetylated tubulin (green), pericentrin (red) and nucleus (blue) in WT, OCRL KO (A3 and A4) in PIP5K1A
KD samples compared with their respective NT CTRL samples. Scale bar: 100 um.
After demonstrating the suitability of our Lowe syndrome model for drug target
validation, we also exploited our model to investigate the disease mechanism further.
Using our in vitro model for Lowe syndrome/Dent II disease, we performed RNA-seq
on tubules formed either from wild-type or OCRL KO cells under fluid flow. We found
161 genes to be differentially regulated in both OCRL KO (A3, A4) cell lines compared
with wild-type HK-2 cells applying a cut off value of an adjusted p-value < 0.05 and a Log
2-fold difference in expression levels (Figure 6a). These 161 genes were further analysed
by performing functional enrichment analysis. Gene ontology (GO) enrichment identified,
in particular, genes that are implicated in EMT and extracellular matrix (ECM)-related
mechanisms (Figure 6b). To validate our RNA-seq results, the upregulation of several genes
of interest was confirmed by quantitative PCR. Specifically, we confirmed upregulation of
SNAI2 and TAGLN, which are both known players in EMT, as well as COL1A1, COL5A1
(fibril forming collagens) and MMP1, which play an important role in fibrosis, a process
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which is characterised by elevated secretion and deposition of ECM proteins (Figure 6c).
Importantly, we were able to show that expression levels of SNAI2 could be rescued after
re-expression of OCRL (Figure 6d).
Figure 6. Differential gene expression: (a) volcano plot showing differentially expressed genes with a cut off of 0.5, and
ECM- and EMT-related genes validated by qPCR are highlighted. (b) Gene Ontology (GO) terms filtered according to 161
differentially expressed genes. The highest score of 32.38, in blue, is the extracellular matrix in the cellular component. 17
(267)—17 genes on our list matched 267 known dysregulated genes in the extracellular matrix cellular component. (c) Other
upregulated genes confirmed by qPCR. Relative gene expression was calculated by 2−∆∆Ct with appropriate housekeeping
genes. (d) SNAI2 expression was upregulated in the absence of OCRL, and the gene expression levels were reduced with
the re-introduction of OCRL–GFP into the cells. Ordinary one-way ANOVA and Dunnett’s multiple comparison test, N = 3
(>50 cells per N). *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001, error bar represents mean with ± SEM.
The upregulation of ECM genes, such as collagen in cells lacking OCRL expression, is
of interest as interstitial fibrosis has been reported in Lowe syndrome. Thus, we investigated
whether lack of OCRL leads not only to elevated collagen gene expression but also to
increased collagen secretion and deposition.
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Using a fluorescence resonance transfer (FRET)-based assay, we could demonstrate
that the amount of pro-collagen I secreted into the medium was elevated for both OCRL KO
cell lines compared to wild-type HK-2 cells. To further confirm that this effect results from
lack of OCRL expression, we generated stable cell lines from our OCRL KO clones A3 and
A4 re-expressing OCRL. Importantly, the increase in elevated collagen secretion reverted
even below wild-type collagen secretion levels after re-expression of OCRL. The fact that
secretion was reduced below wild-type levels was likely due to the strong overexpression
of OCRL compared to endogenous OCRL expression levels (Figure 7).
Figure 7. Collagen secretion: (a) the scheme of the FRET assay used to measure the levels of pro-collagen I in supernatants
of cultured cells. (b) 3D experiment: graph showing quantitative analysis of collagen secretion measured via FRET assay in
cultured cells’ supernatants. Ordinary one-way ANOVA and Dunnett’s multiple comparison test, N = 3 (>50 cells per N),
****, p < 0.0001, error bars represent mean with ± SD. (c) Western blot showing the expression of GFP-tagged OCRL at
approximately 135 kDa in OCRL KO clones with respect to HK-2 WT cell, with the expression of OCRL at approximately
110 kDa. (d) Graph showing the quantitative analysis of collagen secretion measured via FRET assay in cultured cells’
supernatants. Rescue cell lines showing decreased collagen secretion with respect to WT and a scatter dot plot showing the
mean with SD, N = 2.
Finally, we also tested whether the increased pro-collagen I (COL1A1) expression
levels lead to an increase in collagen fibre deposition. Applying a custom-made algorithm
(see Section 4) to identify collagen fibres using collagen immunofluorescence, we quantified
the ratio of cells displaying collagen fibres and quantified their overall intensity. Both
OCRL KO clones showed significantly more cells with collagen fibres and an overall
increase in collagen fibre intensity (Figure 8). Thus, we concluded that lack of OCRL
expression leads to increased pro-collagen I mRNA expression levels, increased collagen
secretion and increased collagen fibre formation, potentially contributing to interstitial
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fibrosis, a phenotype observed in animal model systems for Lowe syndrome and Lowe
syndrome patients.
Figure 8. Collagen deposition: (a) 2D experiment: Immunofluorescence images captured by an InCell
6000 when cells were cultured for 7 days and stained with Col 1 antibody without permeabilising
the cells to stain for ECM deposition (green). Scale bar: 5 µm. (b) 2D experiment: Graph showing
increased ratio of cells with fibrous structures in OCRL KO cells when stained for collagen. (c) 2D
experiment: graph showing increased collagen fibres deposited on OCRL KO cells measured by
normalising the collagen staining intensity by the number of cells. Ordinary one-way ANOVA and
Dunnett’s multiple comparison test, N = 3 (>50 cells per N), ***, p < 0.001; ****, p < 0.0001, error bar
represents the mean with ± SEM.
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3. Discussion
The major cause for decreased life expectancy in Lowe syndrome is the development
of chronic kidney disease and associated complications [38]. Thus, understanding the renal
phenotype in Lowe syndrome is of major importance and the availability of suitable model
systems to study these diseases is critical.
Here, we presented a novel in vitro model for the renal phenotype of Lowe syndrome
using organ on chip technology. Importantly, our model is fully amenable for drug target
identification and validation and is suitable to investigate underpinning molecular disease
mechanisms.
Using CRISPR/Cas9 technology, we generated proximal tubule HK-2 cell lines lacking
OCRL expression. In line with previous reports, such OCRL KO cell lines recapitulate im-
portant phenotypes of Lowe syndrome including reduced megalin-dependent endocytosis
and increased actin polymerisation around endosomes [15–17,34].
We have implemented these cell lines into a microfluidic platform (OrganoPlate) that
allowed for the growth of 3D epithelial tubules together with the application of fluid flow
shear stress [35,36]. It has become clear that 3D architecture and mechanical forces, such
as fluid flow stress, are important regulators of cellular homeostasis and both are lacking
from standard static 2D cultures [39,40]. We demonstrated, here, that under fluid flow,
OCRL KO HK-2 cells have shorter cilia compared to wild-type HK-2 cells. This is in line
with previous reports of impaired ciliogenesis in HK-2 cells lacking OCRL and reduced
cilia length in dermal fibroblasts isolated from Lowe syndrome patients cultured under
static conditions [27,41].
Using cilia length as a readout for the Lowe syndrome phenotype, we demonstrated
that our Lowe syndrome in vitro model can be used for drug target identification, as
we were able to rescue cilia length using an siRNA approach targeting PIP5 kinase α.
Previously, it was shown that knocking down PIP5 kinase α can restore endocytosis
and endosomal F-actin in OCRL knockdown HK-2 cells or ameliorate the pronephric
endocytosis defect in zebrafish [15,17]. Recently, it was also demonstrated that targeting
phosphatidylinositol-3-kinase (PI3kinase) using a small molecule inhibitor approach can
improve proximal tubule function in vitro and in a mouse model of Lowe syndrome and
Dent II disease [34]. Thus, our human in vitro model could also prove useful in small
molecule screens or drug validation, in particular if further improved by replacing HK-2
cells by proximal tubule cells isolated from patients or by generating proximal tubule
cells from induced pluripotent stem cells [41,42]. We demonstrated, recently, the on-chip
differentiation of pluripotent stem cells into intestinal tubules [37].
We also exploited our Lowe syndrome model to further investigate the underpinning
disease mechanisms. The RNA-sequencing experiments performed on 3D tubules grown
in the presence of fluid flow stress revealed significant differences in gene expression
between wild-type and OCRL KO HK-2 cells. Among other proteins, we observed the
upregulation of the transcription factor SNAI2 (also known as Slug) in HK-2 cells lacking
OCRL compared to wild-type OCRL. Importantly, this upregulation was specific to the
OCRL knockout as we could rescue SNAI2 expression levels by re-expressing OCRL in
OCRL KO cells. SNAI2 is a transcription factor playing a major role in development, but
it is also known as a prototypical EMT transcription factor [43]. EMT is the process of
epithelial cells acquiring mesenchymal features. This process plays an important role
during development but also in disease initiation and progression in cancer and fibrosis.
In the context of kidney fibrosis EMT had initially been proposed to be the main process
to generate interstitial myofibroblasts, but lineage tracing experiments confirmed that
only approximately 5% of myofibroblasts trace their origin back to epithelial cells [44].
However, inhibiting EMT by knocking out EMT transcription factors SNAI1 or Twist
selectively in proximal tubule cells reduced ECM deposition and ameliorated interstitial
fibrosis in mouse models of kidney fibrosis [45,46]. Interestingly, in recent years, our view
of EMT has changed dramatically, instead of promoting a fate of either being epithelial
or mesenchymal, it has become clear that EMT reflects rather a continuum of mixed
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phenotypes where epithelial cells acquire different degrees of mesenchymal properties [47].
Thus, proximal tubule cells undergoing EMT usually do not convert into fibroblasts but
remain an integral part of the tubule acquiring only a partial EMT status [44]. This partial
EMT status is associated with changes in the secretome and proliferation rate and promotes
inflammation and fibrosis [45,46].
Our RNA-seq experiments are in line with the idea that HK-2 cells lacking OCRL
undergo partial EMT. We confirmed upregulation of SNAI2 but also of SNAI2 downstream
targets such as MMP1, COL1A1 and COL5A1 [44,48]. Moreover, we also showed that HK-2
OCRL KO cells display increased COL1A1 secretion leading to increased extracellular
collagen fibre deposition, which may contribute to interstitial fibrosis as observed in Lowe
syndrome and Dent II disease patients.
Currently, it is unclear why SNAI2 is upregulated in HK-2 OCRL KO cells; however,
we also observed upregulation of TAGLN and overexpression of TAGLN can promote
EMT in part via upregulation of SNAI2 [49]. TAGLN is a target of TGF-β signalling and
its upregulation could reflect altered TGF-β signalling in HK-2 OCRL KO cells [50]. In
summary, our data suggest that upregulation of SNAI2 and possibly partial EMT could
contribute to the progressive kidney phenotype observed in Lowe syndrome and Dent
II disease; however, confirmation of these results in animal model systems and Lowe
syndrome/Dent II disease patients is necessary.
4. Materials and Methods
4.1. Antibodies and Reagents
The following antibodies were used in this study: Anti-OCRL (HPA012495, 1:500 for
IB and IF, Atlas Antibodies, Bromma, Sweden), N-cadherin (sc-59987, 1:100 for IB, Santa
Cruz Biotechnology, Inc., Dallas, TX, USA), AQP1 (B-11) (sc-25287, 1:500 for IB, Santa Cruz
Biotechnology, Inc., Dallas, TX, USA), Na+/K+-ATPases (H-3) (sc-48345, 1:1000 for IB, Santa
Cruz Biotechnology, Inc., Dallas, TX, USA), EEA1 (610456, 1:500 for IF, BD Biosciences, San
Jose, CA, USA), acetylated tubulin (T6793, 1:2000 for IF, Sigma-Aldrich, St. Louis, MO,
USA), PCNT (ab4448, 1:1000 for IF, Abcam, Cambridge, MA, USA), CI-M6PR 2G11 (ab2733,
1:100, Abcam, Cambridge, MA, USA) along with EEA1 (C45B10, 1:100 for IF), Alexa Fluor™
488 Phalloidin (A12379, 1:4000 for IF, Thermo Fisher Scientific, Waltham, MA, USA), Anti-
GST (27457701, 1:1600 for IF, GE Healthcare, Chicago, IL, USA), collagen I (ab34710, 1:500
for IF, Abcam, Cambridge, MA, USA), PPP1R1A (ab40877, 1:100 for capillary IB, Abcam,
Cambridge, MA, USA), PIP5K1α (9693S, 1:100 for capillary IB, Cell Signaling Technology,
Danvers, MA, USA) and TBP (8515S, 1:500 for capillary IB, Cell Signaling Technology,
Danvers, MA, USA).
Reagents used were TGF-β1 protein (240-B-002, R&D Systems, Minneapolis, MN,
USA), 20 µg/mL, SuperScript™ II Reverse Transcriptase (18064014, Thermo Fisher Scien-
tific, Waltham, MA, USA), Phusion High-Fidelity DNA Polymerase (F530S, Thermo Fisher
Scientific, Waltham, MA, USA), Restriction Enzymes HindIII (FD0504), KpnI (FD0524),
BamHI (FD0055) and NotI (FD0593) were from Thermo Fisher Scientific (Waltham, MA,
USA), Collagen-I (5 mg/mL) (3447-020-01, AMSBIO, Cambridge, MA, USA), 1 M HEPES
(15630-122, Thermo Fisher Scientific, Waltham, MA, USA), NaHCO3, pH 9.5 (Sigma,
S5761), TRITC Dextran 155 kDa (Sigma, T1287), FITC Dextran 20 kDa (FD20S, Sigma-
Aldrich, St. Louis, MO, USA), M-PER™ Mammalian Protein Extraction Reagent (78501,
Thermo Fisher Scientific, Waltham, MA, USA) and Halt Protease and Phosphatase In-
hibitor Complex (78428, Thermo Fisher Scientific, Waltham, MA, USA), ON-TARGETplus
OCRL siRNA (L-010026-00-0005, Dharmacon, Inc., Lafayette, CO, USA), ON-TARGETplus
PIP5K1A Human siRNA (L-004780-00-0005, Dharmacon, Inc., Lafayette, CO, USA) and ON-
TARGETplus Non-targeting pool (D-001810-10-05, Dharmacon, Inc., Lafayette, CO, USA).
4.2. Cell Culture, Gene Editing and Transfection
HK-2 cells were obtained commercially from ATCC. Cells were cultured and main-
tained at 37 ◦C with 5% CO2 in DMEM:F12 HAMs basal medium (11039-021, Thermo
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Fisher Scientific, Waltham, MA, USA) supplemented with 1% of ITS (I1884, Sigma-Aldrich,
St. Louis, MO, USA), 36 ng/mL of hydrocortisone (H0135, Sigma-Aldrich, St. Louis, MO,
USA), 10 ng/mL of hEGF (E9644, Sigma-Aldrich, St. Louis, MO, USA), 40 pg/mL of
3-iodothyronine (T5516, Sigma-Aldrich, St. Louis, MO, USA), 10% of Foetal bovine serum
(16140-071, Thermo Fisher Scientific, Waltham, MA, USA) and 1% of pen/strep (P4333,
Sigma-Aldrich, St. Louis, MO, USA). Cells were passaged 1:4 ratio once 80% confluent and
medium were refreshed every 2–3 days.
Guide RNA sequence ATAATCCAGTTGCATGAGA (target sequence) AGG (PAM)
from Exon 3 was selected using CRISPOR software. The gRNA sequence sub-cloned in the
parent vector pSpCas9(BB)-2A-GFP (PX458) was ordered from GenScript® (Piscataway NJ,
USA). Transfection of the plasmid was performed using Lipofectamine™ 2000 (11668027,
Thermo Fisher Scientific, Waltham, MA, USA) when the cells were 80% confluent. The
cells were starved by leaving the DNA:lipid mixture in reduced serum conditions using
Opti-MEM (11058-021, Thermo Fisher Scientific, Waltham, MA, USA) for 4 h to increase
efficiency. After 48 h, cells were collected and GFP-positive single cells were sorted in
96-well plates using BD FACS Aria II (Flow Cytometry Core Facility, The University of
Sheffield, Sheffield, UK). Colonies were formed from single cells by maintaining the culture
at 37 ◦C with 5% CO2 for 2–3 weeks. These were sequentially expanded, and protein was
extracted from these cells to perform Western blot analysis. Clones with OCRL KO were
then expanded further to use for future experiments. Genomic DNA was extracted from
transfected pool of cells using the Blood & Cell Culture DNA Mini Kit (13323, QIAGEN Inc.,
Germantown, MD, USA) following the manufacturer’s instructions, the region of interest
was amplified and PCR products were sent for sequencing to determine the position of the
in-del and stop codon formation leading to truncation of protein expression.
4.3. T7E1 Assay
Genomic DNA was extracted from transfected pool of cells as mentioned earlier, and
the target gene region in OCRL (Exon 3) was amplified using OCRL specific primers (For-
ward Primer: 5′-CACCACTAGCATCCTTTTAGGC-3′ and Reverse Primer: 5′-AGAGAAA
GTATCATCTCCTCAATGT-3′). T7 Endonuclease I (M0302S, New England Biolabs, Hitchin,
UK) was used to digest PCR products, which were denatured and annealed to facilitate
the formation of heteroduplex DNA. The enzyme was incubated with PCR product for 90
min at 37 ◦C. The reaction was stopped by adding 0.25 M EDTA and the digested products
were separated using 2% agarose gel electrophoresis to check for fragmented DNA.
4.4. GST–RAP Protein Production and Purification
The cDNA was reverse transcribed from the total RNA extracted from HK-2 wild-type
cells. The RAP cDNA was amplified using primers flanked by BamHI and XhoI restriction
sites (Forward primer 5′-GATCGGATCCGGGATGATGGCGCCGCGGAGGGTCA and
Reverse Primer: 3′-GATCCTCGAGTCAGAGTTCGTTGTGCCGAGCTC). The PCR product
was sub-cloned into PGEX-6P-1 vector, which harbours a GST tag sequence before its
multiple cloning site. The cloned plasmid was transformed into BL21(DE3) Competent
Cells (71397-3, Novagen Inc., Madison, WI, USA) and plated on ampicillin resistant agar
plates. A colony was cultured, and protein expression was induced using 1 mM IPTG.
Bacteria were harvested and sonicated to release proteins. Supernatant was incubated
with equilibrated GST beads overnight at 4 ◦C. The GST tagged RAP protein was eluted
and purified using Slide-A-Lyzer™ Dialysis Cassettes (66005, Thermo Fisher Scientific,
Waltham, MA, USA ) with 1X PBS buffer exchange.
4.5. Immunofluorescence Analysis
Co-localisation Assay: Co-localisation analysis was performed on Z stack images
obtained by Perkin Elmer Spinning disc microscopy at 60X magnification using the ImageJ
software plug-in Jacop (Just another co-localization plug-in). Images were thresholded, and
the Pearson coefficient and Mander’s pixel fraction overlapping co-efficient were calculated
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after reducing the background signal by setting-up a threshold. F-Actin quantification:
F-Actin staining intensity was measured in Z stack images acquired by Perkin Elmer
Spinning disc microscopy at 60X magnification using ImageJ software.
GST–RAP Uptake Assay: Appropriate amount of GST-RAP protein was incubated
diluted in DMEM:F12 basal medium for different time points. The cells were washed
with 1X PBS 4 times before proceeding with fixation with 4% PFA and staining to detect
GST–RAP. The images were acquired using the water immersion objective of a confocal
microscope (Perkin Elmer Operetta CLS™, PerkinElmer, Inc., Waltham, MA, USA). The
analysis sequence to quantify GST–RAP was created using Harmony 4.8.2127.198 software.
The imaging protocol 96-well assay plate was set to image 5 fields and two z-planes with a
2 µm separation. Input images were corrected with a basic flat field correction and analysed
on individual planes. Nuclei were identified from the Hoechst 33,342 staining to identify
the number of cells and to serve as a region of interest (ROI) for the cytoplasm detection.
The cytoplasm of the cells was then identified by local intensity thresholding of the Alexa
488 signal. The RAP-positive spots were detected within the entire cell area through a spot
detection step. The mean and sum intensity of the spots were calculated as well as their
area and roundness. The intensities obtained in an image were normalised vs. number of
cells. Mean normalised intensity values across samples were taken into consideration to
quantify the GST–RAP uptake in wild-type HK-2 cells vs. OCRL KO cells.
4.6. GST–RAP Ligand Binding Kinetics
GST–RAP ligand was incubated with cells at different concentrations ranging from
0.5–8 µg/mL (2-fold increase) for 1 h on ice to avoid ligand internalisation by endocytosis.
Cells were washed thrice with basal medium to remove any unbound ligands. Cells were
then incubated with GST antibody conjugated with Alexa-fluor at 488 nm for 1 h (1:100
dilution in FACS staining buffer). Cells were then washed thrice with FACS staining
buffer to remove unbound primary antibody. Cells were analysed with a flow cytometer
and 10,000 events were recorded per sample. Median intensity value from no-ligand
control was subtracted from all other samples to remove background signal. The data were
analysed using GraphPad Prism’s nonlinear regression analysis. Binding saturation with
one site-specific binding model was chosen to derive the Bmax and kd values.
4.7. Homogenous Time Resolved Fluorescence (HTRF) Assay
The HTRF assay kit (63ADK014PEG, Cisbio, Bedford, MA, USA) was used to measure
the amounts of secreted pro-collagen I in the supernatant of cultured cells using the
manufacturer’s instructions. Briefly, 16 µL of supernatants and standard samples were
added to the plate in technical triplicates. Four microliters of diluted Cryptate/d2 antibody
solution were added per well, and the HTRF plate was centrifuged at 1000 RPM for 1 min.
The samples were incubated for 3 hours at RT while covered with a black lid or aluminium
foil to protect from light. The fluorescence of the acceptor molecule was measured using a
plate reader at 665 nm wavelength.
4.8. TGF-β1 Trigger and Collagen Deposition Assay
The TGF-β1 protein was incubated with cells at 10 ng/mL and ALK5-inhibitor
compound was used as a negative control in this assay in a dose–response manner
(0.001–10 µM). Cells stained for collagen deposition were imaged using an Incell 6000
microscope and collagen deposition was measured using an algorithm with three criteria.
Segmentation criteria were set to identify and de-cluster the nucleus such that all cells
were included in the DAPI channel except for ones with uneven and unhealthy-looking
nuclei. The FITC channel with collagen staining was set-up to detect fibre-like structures,
and all the background unspecific noise was cut-off by setting the intensity threshold value
as fibrous-like collagen structures were accumulating and cells were migrating towards
each other. The ratio of cells with a mask created around the cell (cell body) with colla-
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gen fibre-like structures were calculated in each condition vs. cells without the collagen
fibrous structures.
4.9. Proximal Tubule on a Chip Culture
A 3-lane OrganoPlate from Mimetas B.V. (Catalogue Number: 4004-400-B) was used
to culture 3D proximal tubule cultures with HK-2 cells. The middle channel was filled with
2 µL of collagen I, 4 mg/mL after mixing collagen I (5 mg/mL) with 1 M HEPES, pH 7.2–7.5
and NaHCO3, pH 9.5 in 8:1:1 ratio on ice. The plate was incubated at 37
◦C with 5% CO2
in the incubator for 15 min to polymerise the ECM and solidify. The upper channel was
filled with 2 µL of cells such that each chip had 15,000 cells. The plate was kept standing at
a 75◦ angle for 1 h to let all the cells adhere against the ECM. The upper channel outlet was
filled with 50 µL of culture medium and the plate was placed on a rocking platform. The
platform was set to rock and change direction every 8 min at 7◦ angle. The medium was
changed every 2–3 days and tubule formation was complete by day 4 or 5.
4.10. Barrier Integrity Assay
All culture medium was removed from the upper inlet and outlet of the OrganoPlate.
Twenty-five microlitres of medium were added in all inlets and outlets. The plate was kept
on a rocker for 5 min. TRITC 155 kDa and FITC 20 kDa dextran were diluted 1:50 using
culture medium. Twenty microlitres of medium were added in all middle channels and
lower channels inlets and outlets. Forty and thirty microlitres of dextran working solution
were added to the upper channel inlet and outlet, respectively. The plate was imaged by
molecular devices confocal microscope using TRITC and FITC channels. The microscope
was set to take one image of all the chips every 2 min for a time period of 14 min. ImageJ
was used to measure the fluorescence intensity of the top channels vs. the gel channels over
the 14 min time period. The ratio of the signal intensities determined the leak tightness of
the tubules.
4.11. Immunofluorescence in OrganoPlate
Medium was removed from all wells in the OrganoPlate. Fifty microlitres of 4%
PFA were added in the upper channel inlets and outlets to create a gradient such that
the PFA flowed through the lumen of the tubule over an incubation time of 20 min at
room temperature. The PFA was aspirated from all the wells and the plate was washed by
adding 1X PBS like above and incubated for 5 min. This step was repeated 3 times to get
rid of all PFA. The cells were permeabilised by adding the permeabilisation buffer (0.3%
Triton X-100 in 1X PBS) incubated for 10 min at room temperature. The permeabilisation
buffer was removed and washed with washing solution (4% FBS in 1X PBS) for 5 min.
Blocking buffer (2% FBS, 2% BSA, 0.1% Tween20 in 1X PBS) was added and incubated at
room temperature for 1 h. Blocking buffer was removed and desired primary antibody
was diluted in blocking buffer and added in the channels. Forty microlitres in the upper
channel inlet, 30 µL in the upper channel outlet, 20 µL in the lower channel inlet and outlet
and incubated at 4 ◦C overnight. Primary antibody was removed, and channels were
washed with washing solution 3 times for 5 min each. Secondary antibody against the
primary antibody was diluted 1:500 in blocking buffer and was added in the channels and
incubated for 1 h at room temperature. Buffer with secondary antibody was removed and
cells were washed with washing solution thrice for 5 min each. Channels and cells were
washed with 1X PBS once plate was covered in aluminium foil to protect from light.
4.12. RNA Sequencing and Data Analysis
Three biological replicates of 3D HK-2 cells (wild type and OCRL KO) were cultured
in OrganoPlate for 4 days with fluid flow before RNA was isolated and purified from
the OrganoPlate using the RNeasy Micro Kit (74004, QIAGEN Inc., Germantown, MD,
USA). Culture medium was aspirated from the channels and discarded. Forty microlitres
and 30 µL of lysis buffer from the kit were added to the upper channel inlet and outlet,
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respectively and incubated with the cells for 5 min. Lysate from the cells were collected
(70 µL in total), 5 chips were pooled in and 350 µL total lysate was purified using the
columns from the kit following manufacturer’s instructions. Genomic DNA was removed
using DNASE I treatment which is part of the kit. Purified RNA’s concentration and purity
was measured using Nanodrop and 5200 Fragment Analyzer (M5310AA, Agilent, Santa
Clara, CA, USA) following the manufacturer’s instructions.
To perform standard RNA-seq, 10 µL of RNA with minimum concentration of 50 ng/µL
was sent to GENEWIZ, LLC. (South Plainfield, NJ, USA), which performed RNA library
preparation with polyA selection for sequencing with Illumina HiSeq, 2 × 150 bp configu-
ration, single index, per lane. The ~350 M raw paired-end reads per lane per sample was
provided after sequencing, and the bio-informatics team at Galapagos BV performed the
data analysis. Briefly, raw data were pre-processed using a workflow consisting of trim-
ming reads to remove adapters, indexes and bad-quality bases using Trimmomatric [51]
and quality control on trimmed reads using FastQC. Filtered reads were aligned/mapped
to the reference genome build using STAR [52] and pseudo-mapped against the reference
transcriptome using Kallisto [53]. The mapping quality was assessed focusing on coverage
of splice junctions; rates of splicing in known or novel junctions; read coverage of splice
junctions; gene body coverage and potential 5′-3′ bias; insertions–deletions: the rate of
occurrence and the lengths using QoRTS [54]. The estimated counts from the Kallisto
abundance estimations (at the transcript level) were summarized at the gene-level by using
the R package txtimport [55] using Ensembl annotations and DESeq2 (R/Bioconductor
package) is used to fit a negative binomial model to the data [56]. Results tables with
the main outputs the log2-fold change (FC), p-values and adjusted p-values (false discov-
ery rate–FDR) were generated from which the volcano plot and gene ontology analysis
were performed.
4.13. RNA Interference, Reverse Transcription and Quantitative PCR (qPCR)
The siRNA transfection in OrganoPlate was performed by diluting the siRNA’s in
Opti-MEM to a final optimised concentration. Lipofectamine RNAiMAX Transfection
Reagent was diluted 1:50 with Opti-MEM. The siRNA:lipid were mixed in a 1:1 ratio and
left to incubate at RT for 15–20 min to form RNA:lipid complexes. During the above
incubation, medium from the plates were removed and 50 µL was added in the upper
channel inlet and outlet. Ten microlitres of siRNA/RNAiMAX complexes were added to
the upper channel inlet and outlet. Plates were then incubated at 37 ◦C, 5% CO2 on a rocker
set at 7◦ angle to change every 8 min for 48 h before cells were harvested for RNA/protein
isolation for further analysis as described earlier.
The RNA was used to reverse transcribe to get cDNA using TaqMan Reverse Tran-
scription Kit (N8080234, Applied BioScience, Foster City, CA, USA). The cDNA was serially
diluted 2× times and amplification efficiency of both target gene and housekeeping gene
using Taqman probes was compared to choose the right housekeeping gene to normalise
for relative quantification of gene expression levels. The qPCR was performed using Light
Cycler 480™ (Roche, Basel, Switzerland), Ct values obtained for both target gene (FAM
dye) and housekeeping gene (VIC dye) were used to calculate relative gene expression
levels using Livak method (2−∆∆Ct method).
List of Assay IDs used for Taqman probes: SNAI2-Hs00161904_m1; COL1A1-Hs0016
4004_m1; COL5A1-Hs00609088_m1; TAGLN-Hs00162558_m1 and MMP1-Hs00899658_m1.
4.14. Statistics and Data Analysis
All statistical analyses were performed using GraphPad Prism software. Statistical
significance of the data obtained from multiple independent experiments were tested
using the t-test for two data sets or ordinary one-way ANOVA and Dunnett’s multiple
comparison test for more than two groups unless otherwise specified. Co-localisation
analysis was performed using Mander’s overlap co-efficient using the Jacop plug-in from
ImageJ software.
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